openPR Logo
Press release

InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct®

03-07-2012 01:49 AM CET | Health & Medicine

Press release from: InDex Pharmaceuticals

/ PR Agency: akampion
-- TLR9 Agonist for the Treatment of Chronic, Active, Treatment-Refractory Ulcerative Colitis --

Stockholm, March 6, 2012 - InDex Pharmaceuticals today announced the start of the COLLECT trial, a European multicenter Phase III study to evaluate the effectiveness and safety of Kappaproct for the treatment of chronic active ulcerative colitis (UC) patients not responding to available therapy. Kappaproct is a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9).

UC is a chronic, relapsing-remitting disease caused by inflammation of the colon. Although current UC treatments are effective for many patients with mild to moderate disease, a significant unmet medical need still exists for patients with severe UC. Many of these patients have failed all available pharmaceutical therapies - therefore, surgical removal of the colon by partial or complete colectomy is currently the only remaining treatment option.

The primary endpoint of the COLLECT study is induction of clinical remission in these severe UC patients, who have failed all other medical treatments and have been elected for colectomy. Preliminary results are expected for Q1, 2014.

“Today, a significant portion of ulcerative colitis patients will eventually have their colons removed because of severe illness. Our goal is to show that Kappaproct induces clinical remission in these patients, who are facing highly invasive surgery associated with potential risks and complications, including a long-term negative impact on the quality of life. Successful treatment with Kappaproct resulting in remission, thereby avoiding surgery, would dramatically improve the lives and prospects of these very ill patients,” said Jesper Wiklund, CEO of InDex Pharmaceuticals.

###

About the COLLECT study
COLLECT is a double-blind, placebo-controlled phase III study, in which 120 treatment refractory UC patients are being randomized in a 2:1 ratio of receiving either Kappaproct or placebo intracolonically. Kappaproct or placebo will be administered as an add-on treatment, allowing all study patients to remain on concomitant medication throughout the study. The study will be conducted at 36 sites in six European countries. More information about the study can be found on clintrials.gov with the ClinicalTrials.gov Identifier NCT01493960.

About Kappaproct
Kappaproct is a single-stranded, DNA-based synthetic oligonucleotide. It functions as an immuno-modulatory agent by targeting TLR9. In a Phase II trial, Kappaproct has shown positive effects in the treatment of steroid-resistant UC patients, including induction of long-term steroid free remission. In a compassionate use program, Kappaproct was able to induce clinical remission at week 12 in 10 out of 14 (71%) treatment-refractory UC patients that had been elected for colectomy. Kappaproct has received orphan drug designation in Europe.

About InDex Pharmaceuticals
InDex Pharmaceuticals is a biopharmaceutical company focusing on the discovery and development of immunology based treatments exclusively addressing disease states with a high unmet medical need. InDex Pharmaceuticals is also dedicated to personalized medicine and is developing companion diagnostics that will allow for the precise selection of only those patients likely to respond to a treatment. InDex Pharmaceuticals was founded in 2000 and is located in Stockholm, Sweden.

For additional information about COLLECT, Kappaproct and InDex Pharmaceuticals, please visit www.indexpharma.com.

Jesper Wiklund, CEO

InDex Pharmaceuticals AB
Scheeles väg 2
SE-171 77 Stockholm, Sweden

Phone: +46 (0)8 508 847 30
Fax: +46 (0)8 508 847 39
E-mail: info@indexpharma.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct® here

News-ID: 213252 • Views: 1279

More Releases from InDex Pharmaceuticals

InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Res …
Stockholm, October 24, 2012 – InDex Pharmaceuticals today announced that it has been granted a Japanese patent by the Japan Patent Office (JPO). The patent provides protection for the use of Kappaproct® and other DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema, and chronic obstructive pulmonary disease. The patent, entitled “Immunostimulatory Method” covers the use of a broad range
Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ul …
- InDex Pharmaceuticals reports positive clinical data in peer-reviewed journal Inflammatory Bowel Diseases - Stockholm, June 19, 2012 – InDex Pharmaceuticals today announced the publication of positive data from the Company's compassionate use program with its lead compound Kappaproct. In the program, eight treatment-refractory ulcerative colitis (UC) patients that had been elected for colectomy received Kappaproct, a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9). The findings showed that
InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member
- Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network - Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke Pedersen has been appointed as a new member of the Board of Directors. Mr. Pedersen brings to InDex Pharmaceuticals over 25 years of longstanding life sciences industry experience in commercial operations and leadership. Mr. Pedersen previously served as Executive Vice President of Commercial Operations at
InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant …
Stockholm, April 26, 2012 – InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease. The patent, entitled “Method for Modulating Responsiveness to Steroids”

All 5 Releases


More Releases for Kappaproct

InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Res …
Stockholm, October 24, 2012 – InDex Pharmaceuticals today announced that it has been granted a Japanese patent by the Japan Patent Office (JPO). The patent provides protection for the use of Kappaproct® and other DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema, and chronic obstructive pulmonary disease. The patent, entitled “Immunostimulatory Method” covers the use of a broad range
Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ul …
- InDex Pharmaceuticals reports positive clinical data in peer-reviewed journal Inflammatory Bowel Diseases - Stockholm, June 19, 2012 – InDex Pharmaceuticals today announced the publication of positive data from the Company's compassionate use program with its lead compound Kappaproct. In the program, eight treatment-refractory ulcerative colitis (UC) patients that had been elected for colectomy received Kappaproct, a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9). The findings showed that
InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member
- Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network - Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke Pedersen has been appointed as a new member of the Board of Directors. Mr. Pedersen brings to InDex Pharmaceuticals over 25 years of longstanding life sciences industry experience in commercial operations and leadership. Mr. Pedersen previously served as Executive Vice President of Commercial Operations at
InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant …
Stockholm, April 26, 2012 – InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease. The patent, entitled “Method for Modulating Responsiveness to Steroids”
InDex Pharmaceuticals Expands Management Team
- InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer - Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions to its management team: Pernilla Sandwall has been appointed as Head of Clinical Operations and Thomas Knittel as Chief Medical Officer. Pernilla Sandwall will lead the company’s clinical development team, with the main focus being the ongoing phase III clinical trial of Kappaproct®
InDex Pharmaceuticals Develops Companion Diagnostic Test for New Ulcerative Coli …
- Personalized treatment option for patients with refractory ulcerative colitis - Stockholm, March 20, 2012 - InDex Pharmaceuticals today announced the development of a companion diagnostic test for Kappaproct®. Kappaproct, the lead product candidate of InDex, is currently in a phase III study as a treatment for chronic active, treatment refractory ulcerative colitis. In this study, the companion diagnostic test is being evaluated to demonstrate a correlation between test result and